Clinical trials: Ranibizumab
Choroidal Melanoma
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
The purpose of the study is to investigate the safety and tolerability of the anti-VEGF (vascular endothelial cell growth factor) treatment, ranibizumab, in combination with proton beam irradiation for the treatment of choroidal…
- Trial name
- NCT00765921
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Diabetic Macular Edema
Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema
PURPOSE: To evaluate the effect of the vitreous in response to intravitreal (IV) injections of ranibizumab 0.5 mg/0.05ml (Lucentis; Genentech, South San Francisco, CA) for the treatment of diabetic macular edema (DME).
- Trial name
- DEVITRA (NCT04387604)
- Testing
- Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
- Where
- Portugal
- Volunteers
- 50 people
- Sponsor
- Centro Hospitalar do Porto
Glaucoma, Neovascular, Ranibizumab
Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study
Neovascular glaucoma is a potentially blinding condition characterized by the growth of newvessels at the anterior part of the eye.
- Trial name
- NCT02914626
- Testing
- Intravitreal ranibizumab
- Volunteers
- 28 people
- Sponsor
- LEANDRO CABRAL ZACHARIAS
Choroidal Neovascularization
Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy
The primary objective: *To measure the difference in the number of Ranibizumab therapies needed in 12 months in the Posterior Vitreous Detachment (PVD) positive and Posterior Vitreous Detachment (PVD) negative group.
- Trial name
- PVD (NCT01256632)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vision Research Foundation
Age Related Macular Degeneration
Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy
The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on…
- Trial name
- FVF4193s (NCT01255774)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The New York Eye & Ear Infirmary
Central Retinal Vein Occlusion
Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
The purpose of this study is to compare ranibizumab injection to hemodilution at the early phase of Central Retinal Vein Occlusion (CRVO) and to determine if the combination of both treatments may have a synergic effect.
- Trial name
- CHIC-3 (NCT01448018)
- Testing
- ranibizumab, hemodilution
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Fibrovascular Pigment Epithelial Detachment
Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
This is an open label study to evaluate the efficacy of intravitreal aflibercept injection 2mg in patients with a persistent FVPED despite at least 6 consecutive injections with ranibizumab 0.5 mg.
- Trial name
- NCT01495208
- Testing
- Aflibercept
- Where
- United States
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Choroidal Melanoma
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that…
- Trial name
- NCT01251978
- Testing
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New England Retina Associates
Branch Retinal Vein Occlusion
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- NCT04667897
- Testing
- 601 1.25mg, Ranibizuman 0.5 mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Neovascular Age-related Macular Degeneration
A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly…
- Trial name
- NCT03345082
- Testing
- OPT-302, ranibizumab
- Where
- 108 sites in United States, Czechia and 8 more
- Volunteers
- 366 people
- Sponsor
- Opthea Limited
Retinopathy of Prematurity
Refractive Error and Biometry in Retinopathy of Prematurity
The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.
- Trial name
- NCT03334513
- Testing
- Bevacizumab, Ranibizumab
- Volunteers
- 35 people
- Sponsor
- San Ni Chen
Diabetic Retinopathy, Retinal Neovascularization
Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy
The purpose of this study is to evaluate the effects of panretinal photocoagulation plus intravitreal ranibizumab for the treatment of patients with high risk proliferative diabetic retinopathy in terms of changes in visual…
- Trial name
- IRaHi (NCT01102946)
- Testing
- Ranibizumab, Panretinal Photocoagulation
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo
Diabetic Retinopathy, Retinal Detachment
Ranibizumab for Diabetic Traction Retinal Detachment
The purpose of this study was to assess the effect of ranibizumab in reducing intraoperative vitreous haemorrhage during pars plana vitrectomy, thus facilitating surgery and improving its anatomical and functional results in…
- Trial name
- RANITRA (NCT01201161)
- Testing
- Ranibizumab
- Where
- Brazil
- Volunteers
- 19 people
- Sponsor
- University of Sao Paulo
Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)
Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal…
- Trial name
- NCT00284089
- Testing
- Ranibizumab
- Where
- Japan
- Volunteers
- 88 people
- Sponsor
- Novartis
Proliferative Diabetic Retinopathy, Diabetic Retinopathy
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.
In prolifertive diabetic retinopathy (PDR) eyes with bleeding known as vitreous hemorrhage (VH) requiring a surgical procedure to remove the vitreous, called a vitrectomy, we will determine if the benefit and safety of adding a…
- Conditions
- Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
- Trial name
- 4 PORT (NCT07864480)
- Testing
- PDS Implant filled with 100 mg/mL Ranibizumab, Ranibizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Southeast Retina Center, Georgia
Choroidal Neovascularization
Intraocular Pressure Immediately Following Intravitreous Injection of Ranibizumab
This study will quantify the intraocular pressure elevation in the immediate time period following intravitreous injection. With more widespread use of intravitreous injections in patients that may require several injections per…
- Trial name
- NCT00417703
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Oklahoma State University Center for Health Sciences
Macular Degeneration, Choroidal Neovascularization
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).
- Trial name
- BGB/IST (NCT00533520)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Brandon G. Busbee, MD
Proliferative Diabetic Retinopathy
Retrospective Review of Proliferative Diabetic Retinopathy Patients
The primary objective of the protocol is to determine if intravitreal ranibizumab alone decreases retinal neovascularization from Proliferative Diabetic Retinopathy (PDR) with deferred panretinal photocoagulation (PRP) and/or…
- Trial name
- NCT03609996
- Testing
- Panretinal Photocoagulation, Lucentis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Elman Retina Group
Neovascular Age-Related Macular Degeneration
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
The PrONTO Study was designed to evaluate the response of neovascular age-related macular degeneration (AMD) patients to intravitreal Lucentis using Optical Coherence Tomography (OCT) imaging.
- Trial name
- NCT00344227
- Testing
- Lucentis (Ranibizumab)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Retinal Diseases
Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema
The purpose of this study in to compare the efficacy of treatment of diabetic macular edema (DME) using Ranibizumab (Lucenti®), Aflibercept (Eylea®) and Aflibercept (Eylea®) plus Ranibizumab (Lucentis®).
- Trial name
- NCT02646670
- Testing
- Ranibizumab, Aflibercept, Ranibizumab and Aflibercept
- Volunteers
- 20 people
- Sponsor
- Instituto de Olhos de Goiania